Exicure (XCUR) Total Non-Current Liabilities (2016 - 2026)
Exicure (XCUR) reported Total Non-Current Liabilities of $4.9 million for Q1 2026, up 24.69% on a YoY basis from $3.9 million in Q1 2025, and up 13.27% quarter-over-quarter from $4.3 million in Q4 2025.
Exicure (XCUR) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Exicure has reported Total Non-Current Liabilities for 10 years, with the latest figure at $4.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 24.69% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 24.69% YoY), and the FY2025 full-year result was $4.3 million, down 47.96% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $4.9 million, up from $4.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $38.7 million in Q1 2022, with the low at $2.8 million in Q3 2025.
- Historically, Total Non-Current Liabilities has averaged $14.4 million across 4 years, with a median of $6.6 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 84.13% — and 2026, when it advanced 24.69%.
- Exicure's Total Non-Current Liabilities stood at $8.4 million in 2022, then fell by 1.45% to $8.3 million in 2024, then slumped by 47.96% to $4.3 million in 2025, then rose by 13.27% to $4.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $4.9 million (Q1 2026), $4.3 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | 4.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.88 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | 8.28 Mn |
| Dec 31, 2022 | 8.41 Mn |
| Sep 30, 2022 | 32.65 Mn |
| Jun 30, 2022 | 35.79 Mn |
| Mar 31, 2022 | 38.66 Mn |
| Dec 31, 2021 | 52.98 Mn |
| Sep 30, 2021 | 63.26 Mn |
| Jun 30, 2021 | 37.17 Mn |
| Mar 31, 2021 | 37.25 Mn |
| Dec 31, 2020 | 38.28 Mn |
| Sep 30, 2020 | 37.85 Mn |
| Jun 30, 2020 | 14.37 Mn |
| Mar 31, 2020 | 20.37 Mn |
| Dec 31, 2019 | 34.52 Mn |
| Sep 30, 2019 | 8.71 Mn |